Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances

Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here. Apis Flagship Fund delivered strong performance in the fourth quarter of 2025, with the Fund up 10.0% net for the quarter and gaining 55.1% for the full year, significantly outperforming the MSCI ACWI global benchmark by approximately 7.0% in Q4 and 33.0% for the year. Long positions drove the majority of gains as they generated 11.9% gross contribution, while shorts added a further 0.8% gross, with the portfolio positioned around 68% net long as of December. Performance was broad-based, as Technology and Healthcare led quarterly returns, and strong contributions also came from basic materials, while small-capitalization stocks narrowed their traditional underperformance relative to large caps. Looking ahead, the firm highlighted its continued emphasis on bottom-up stock selection, structural exposures to niche opportunities across healthcare, semiconductors, and industrials, and the persistent attractiveness of non-U.S. markets as key drivers for future potential returns. In addition, please check the Fund’s top five holdings to know its best picks in 2025.

In its fourth-quarter 2025 investor letter, Apis Capital Advisors highlighted stocks like Celcuity Inc (NASDAQ:CELC). Celcuity Inc (NASDAQ:CELC) is a clinical-stage biotechnology company developing precision oncology therapies using its CELsignia platform to identify cancer patients most likely to benefit from targeted treatments. The one-month return of Celcuity Inc (NASDAQ:CELC) was 5.41% while its shares traded between $7.58 and $120.32 over the last 52 weeks. On January 30, 2026, Celcuity Inc (NASDAQ:CELC) stock closed at approximately $109.42 per share, with a market capitalization of about $5.06 billion.

Apis Capital Advisors’ Apis Flagship Fund stated the following regarding Celcuity Inc (NASDAQ:CELC) in its Q4 2025 investor letter:

“Stock selection was the primary driver of performance in the fourth quarter, with long positions generating returns more than three times benchmark levels, while short positions also contributed modestly. All regions and sectors were positive – North America and Asia accounted for the majority of gains, while Europe contributed less but generally in line with its regional weighting. From a sector perspective, Technology and Healthcare led quarterly performance. The top contributor in Q4 was Celcuity Inc (NASDAQ:CELC), a healthcare name highlighted in our last quarterly letter, which added 3.8% during the quarter and 4.4% for the full year. “

Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances

Billion Photos/Shutterstock.com

Celcuity Inc (NASDAQ:CELC) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 31 hedge fund portfolios held Celcuity Inc (NASDAQ:CELC) at the end of the third quarter, which was 15 in the previous quarter. While we acknowledge the risk and potential of Celcuity Inc (NASDAQ:CELC) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Celcuity Inc (NASDAQ:CELC) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Celcuity Inc (NASDAQ:CELC) and shared the list of the best performing stocks in 2025. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.